Evidence map›Paper›PMID 41750582›Full record

ArticleAntioxidants (Basel, Switzerland)2026

A Pathophysiological Model of Parkinson's Disease Based on Microvascular Flow Disturbance and Leukocyte-Mediated Oxidative Injury in Critical Pigmented Neuronal Niches.

Emilio Fernández-Espejo, Fernando Rodríguez de Fonseca

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Emilio Fernández-EspejoRoyal College of Physicians of Seville, 41013 Seville, Spain.ORCID 0000-0003-0724-6049
Fernando Rodríguez de FonsecaUnidad Clínica de Neurología, Instituto de Investigación Biomédica de Málaga & Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Hospital Regional Universitario, 29590 Málaga, Spain.ORCID 0000-0002-4516-5795

Funding

Instituto de Salud Carlos III ERDF-EU-RD21/0009/0003Instituto de Salud Carlos III RD06/001/002Instituto de Salud Carlos III RD21/0009/0003Junta de Andalucía Neuro-RECA-RIC-0111-2019Sociedad Andaluza de Neurología SUBAIA2015/006
6 · The paper itself

Abstract

The authors hypothesize that idiopathic Parkinson's disease may result from an alteration in microvascular flow at a "critical point" in the nervous system that is characterized by pigmented cells that express neuromelanin and/or lipofuscin. "Critical points" include the olfactory epithelium/bulb, the autonomic nervous system, the enteric nervous system, the prefrontal-cortico-pontine network, and the amygdala. Hypoxia-ischemia following blood flow disturbance would recruit and activate leukocytes and induce the infiltration of peripheral immune cells into neural tissue. The excess of toxic factors produced by hyperactive immune cells, such as myeloperoxidase and its derivatives, would cause the oxidation of lipids, proteins, and biogenic monoamines such as dopamine, which in turn would facilitate the accumulation and precipitation of neuromelanin, lipofuscin, and alpha-synuclein. In addition, neuromelanin and lipofuscin precipitates may accentuate the misfolding and aggregation of alpha-synuclein. This "amplification" mechanism could help explain the crucial role of pigmented neurons in the onset of Parkinson's disease pathology, triggering abnormal neurotoxic alpha-synuclein spread throughout the nervous system from the "critical point" of origin, and enabling a self-perpetuating degenerative process. The proposed hypothesis may have implications for the identification of new therapeutic targets, early prevention strategies, and the development of vascular and/or immune biomarkers.

Indexed as

alpha-synucleinblood flow disturbancedopamine oxidationleukocytelipofuscinmodelmyeloperoxidaseneuromelaninParkinson’s disease

Identifiers

PMID41750582
PMCPMC12938327

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.